Japan Pulmonary Arterial Hypertension Drug Market

Japan Pulmonary Arterial Hypertension Drug Market Size Report – In a Glance

As per the survey report on Japan pulmonary arterial hypertension drug market, the market is expected to foresee a CAGR value of 5.6% during 2025-2035, and further generate a market size of USD 815.3 Million by the end of 2035. In 2025, the market size was value at USD 495.7 Million revenue.

• The Japan pulmonary arterial hypertension drug market’s growth is influenced by the rising awareness about preventive healthcare and drugs availability in the market.
• KDMI analyst’s growth analysis foresees high treatment costs as the market restraint for Japan pulmonary arterial hypertension drug market.

Japan Pulmonary Arterial Hypertension Drugs Market Analysis

Pulmonary arterial hypertension drugs are used to relax pulmonary arteries in the lungs with the aim to improve blood flow. Pulmonary arterial hypertension is a complex disease in which the pressure on arteries is increased to carry blood from heart to lungs. The common symptoms of pulmonary arterial hypertension is shortness of breath, swelling of ankles and legs, dizziness, and fainting. The market growth is influenced by rising awareness of availability of drugs to provide preventive care for such chronic diseases and implementation of advanced technology has resulted into enhancement of diagnostic tools. The reports show, the prevalence of pulmonary arterial hypertension was 3.2 per 100,000 and there are nearly 70-100 cases per year. GSK plc, Sandoz Group AG, and Viatris Inc are some of the significant participants in the Japan pulmonary arterial hypertension drugs market.

Japan Pulmonary Arterial Hypertension Drugs Market Growth Drivers and Restraints

Growth Drivers

• Advancements in Medical Research and Drug development – Advancement in medical research and drug development are the significant factors that drives the Japan pulmonary arterial hypertension drugs market growth. The adoption of advancement in technology in healthcare sector have resulted in the enhancement of diagnostic tools, drug efficacy and safety. The government initiatives and regulations promoting investments in medical research and drug development have led the increased emphasis on manufacturers to produce tools by identifying new molecular and genetic targets for therapy sessions. The Japan Agency for Medical Research and Development (AMED) is a regulating body for medical research and provides regulation for the development need in the sector to boost medical services.
• Rising awareness and diagnosis Rates – Rising awareness about prevalence and diagnosis rates are driving the market growth with the greatest participation from people, early detection, and increasing patient awareness. The government initiatives in organizing campaigns to create awareness and increasing early detection has led to the increased focus of medical professionals for disease prevalence. The increased patient engagement has led the development of drug efficiency in dealing with diseases like pulmonary arterial hypertension. Causes of such diseases are increased level of stress, workload pressure, and others affects the heart health of people leading to rise in incidence of cardiovascular and related diseases. Therefore, the rising awareness positively impacts the growth of pulmonary arterial hypertension drugs market.

Restraints

• High treatment costs – The major challenge for Japan pulmonary arterial hypertension drug market is high treatment costs. The treatment process of pulmonary arterial hypertension disease is expensive which is least preferable by middle-aged income group. The therapies including endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, and prostacyclin analogues are relatively expensive. The fluctuations in raw material prices affects the drug development and productions costs, leading to highly expensive drugs in the market. These factors affect the market growth due to least preferability from low-income group of people.

Japan Pulmonary Arterial Hypertension Drugs Market Segmentation

Our experts at KD Market Insights, have segmented the Japan pulmonary arterial hypertension drugs market research report as:

Analyst’s observation on Japan Pulmonary Arterial Hypertension Drugs Market Recent Developments

Over the years, the experts at KD Market Insights have been observing the recent developments associated with Japan pulmonary arterial hypertension drugs market trends. Our expert’s market forecast analysis has recorded the market players adopting plentiful of key strategies including new product launches, mergers & acquisitions, and collaborations.

Nippon Shinyaku Co ltd have announced the launch of Uptravi tablets for pediatric 0.05 mg for treating pulmonary arterial hypertension in the country with the aim to reduce pulmonary arterial pressure by combining to the IP receptors and increasing cAMP production, resulting in the vasodilation and inhibition of vascular smooth muscle accumulation.

Moreover, Mochida Pharmaceutical has acquired the Japanese distribution rights of Tyvaso DPI, an inhalation powder developed from Treprostinil, for the treatment of pulmonary arterial hypertension and associated health risks. Now, after acquisition Mochida Pharmaceutical has all the rights from marketing to selling of the drug in the Japan market.

Japan Pulmonary Arterial Hypertension Drug Market Competitive Landscape

Some of the significant participants who top the Japan pulmonary arterial hypertension market growth:

• GSK PLC
• Teva Pharmaceutical Industries Ltd.
• United Therapeutics Corporation
• Dr. Reddy’s Laboratories Ltd.
• Sandoz Group AG
• NATCO Pharma Limited
• Zydus Pharmaceuticals, Inc
• Hikma Pharmaceuticals PLC
• Viatris Inc
• Sun Pharmaceutical Industries Ltd